xmab23104
mAbexperimentalMulti-specific
Clinical trial activity
3 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2019 (NCT03752398)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Transitional Cell · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 1
- Esophageal Neoplasms · Phase 1
- Melanoma · Phase 1/Phase 2
- Nasopharyngeal Carcinoma · Phase 1
- Neoplasms · Phase 1
- Pancreatic Neoplasms · Phase 1
- Sarcoma · Phase 2
- Small Cell Lung Carcinoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Uterine Cervical Neoplasms · Phase 1
Mechanism of action
- Programmed cell death protein 1INHIBITOR
PDCD1 inhibitor
- Inducible T-cell costimulatorINHIBITOR
ICOS inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05879185 | Phase 2 | Apr 6, 2023 | Memorial Sloan-Kettering Cancer Center, Xencor |
| NCT05695898 | Phase 1/Phase 2 (Phase 2) | Feb 28, 2023 | University of California, San Francisco, Xencor |
| NCT03752398 | Phase 1 | May 1, 2019 | ICON, Xencor |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Xencor | For profit | 3 | 1 | 2 | 2019 |
| ICON | For profit | 1 | 0 | 1 | 2019 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2023 |
| University of California, San Francisco | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1